EUCTR2012-003489-42-SE进行中（未招募）1 期
An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent must be obtained from a legally acceptable representative (eg, guardian or caregiver), in accordance with requirements of the trial center’s IRB/IEC, prior to the initiation of any protocol-required procedures. In addition, the subject, as required by the trial center’s IRB/IEC, must provide informed assent at Baseline and as such must be able to understand that he or she can withdraw from the trial at any time.
- •2. The subject and the designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator.
- •3. The subject completed Trial 31-12-293. Subjects who completed the Week 8 visit of Trial 31-12-293 are defined as trial completers.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 96
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The subject experienced AEs during the double-blind trial that would, in the investigator's judgment, preclude further exposure to aripiprazole.
- •2. The subject had protocol violations during the double-blind trial considered major in the judgment of the investigator (significant noncompliance, use of prohibited concomitant medications, concern with use of drugs of abuse, etc.), which would deem them poor candidates for this trial.
- •3. A positive drug screen at Baseline (ie, Day 0/last visit of double-blind trial, Protocol 31-12-293) for cocaine, alcohol, or other drugs of abuse (excluding caffeine, nicotine, or prescribed psychostimulants for ADD/ADHD) which will result in early termination on Week 1.
- •4. Sexually active males who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 90 days following the last dose of study drug, or sexually active females of childbearing potential who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 30 days following the last dose of study drug. Abstinence will be permitted if it is confirmed and documented at every trial visit. If employing birth control, 2 of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control depot injections, implant, condom, or sponge with spermicide.
- •5. Females who have a positive urine pregnancy test result prior to receiving trial drug, or are pregnant or lactating.
- •6. The subject represents a significant risk of committing suicide based on a routine psychiatric status examination, investigator’s judgment or who have an answer of yes” on any question other than 1-3 on the C-SSRS.
- •7. Body weight is lower than 16 kg.
- •8. The following vital signs and ECG results are exclusionary:
- •1) Diastolic blood pressure > 105 mmHg
- •2) QTc = 450 msec on either the QTcB (Bazett’s) or QTcF (Fridericia) corrections on 2 of 3 time points (see NOTE below)
- •The following laboratory test results will result in discontinuation at the Week 1 visit:
- •1) Platelets = 75,000/mm3
- •2) Hemoglobin = 9 g/dL
- •3) Neutrophils, absolute = 1000/mm3
- •4) Aspartate aminotransferase (AST) > 3 x ULN as defined by the central laboratory
- •5) Alanine aminotransferase (ALT) > 3 x ULN as defined by the central laboratory
- •6) Creatinine = 2 mg/dL
- •NOTE: In addition, subjects should be excluded (or discontinued at the Week 1 visit for abnormal laboratory tests) if they have any other vital sign results or ECG findings which in the investigator’s judgment are medically significant and would impact the safety of the subject or the interpretation of the trial results. Criteria are provided in the protocol to assist investigators in their assessments of results that may be potentially medically significant, depending on the subject’s medical history and clinical presentation.
研究者
相似试验
进行中（未招募）
不适用
A global study to see how safe and effective a Once-weekly tablet containing Aripiprazole is in Children and Adolecents with Tourette's DisorderTourette’s DisorderMedDRA version: 16.0Level: PTClassification code 10044126Term: Tourette's disorderSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000469-11-BGOtsuka Pharmaceutical Development & Commercialization, Inc.156
进行中（未招募）
1 期
A clinical trial to test the safety of aripiprazole in children and adolescents with Tourette’s DisorderTics associated with Tourette’s Disorder in children and adolescentsMedDRA version: 14.1Level: PTClassification code 10044126Term: Tourette's disorderSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003489-42-NLOtsuka Pharmaceutical Development & Commercialization, Inc.96
进行中（未招募）
1 期
A clinical trial to test the safety of aripiprazole in children and adolescents with Tourette’s DisorderEUCTR2012-003489-42-DEOtsuka Pharmaceutical Development & Commercialization, Inc.96
进行中（未招募）
不适用
A clinical trial to test the safety of aripiprazole in children and adolescents with Tourette’s DisorderTics associated with Tourette’s Disorder in children and adolescentsMedDRA version: 14.1Level: PTClassification code 10044126Term: Tourette's disorderSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003489-42-HUOtsuka Pharmaceutical Development & Commercialization, Inc.96
进行中（未招募）
1 期
A clinical trial to test the safety of aripiprazole in children and adolescents with Tourette’s DisorderTics associated with Tourette’s Disorder in children and adolescentsMedDRA version: 14.1Level: PTClassification code 10044126Term: Tourette's disorderSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2012-003489-42-BEOtsuka Pharmaceutical Development & Commercialization, Inc.96